Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of Salix Pharmaceuticals, Ltd.

WASHINGTON--(BUSINESS WIRE)--

The law firm of Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Salix Pharmaceuticals, Ltd. (NASDAQ GS: SLXP), concerning the Company's proposed acquisition by Valeant Pharmaceuticals International, Inc. VRX. Under the terms of the proposal, Salix shareholders will receive $158.00 in cash for each share of Salix common stock they own. At least one analyst has set a high target price of $185.00 for Salix shares. The entire transaction is valued at approximately $14.5 billion.

The investigation is focused on whether Salix's Board of Directors breached its fiduciary duty in failing to maximize consideration to shareholders, the potential unfairness of the consideration to shareholders, the process by which the Board of Directors considered the transaction, and potential conflicts of interest among the Salix's Board of Directors' members.

If you are interested in discussing your rights as a Salix shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or (202) 337-8000, or by email at contact@finkelsteinthompson.com.

Finkelstein Thompson LLP has spent over three decades delivering outstanding representation to institutional and individual clients in financial litigation, and has been appointed as lead or co-counsel in dozens of shareholder class actions. Indeed, the firm has served in leadership roles in cases that have recovered over $1 billion for investors and consumers.

To learn more about Finkelstein Thompson LLP, please visit our website at www.finkelsteinthompson.com. Attorney advertising. Prior results do not guarantee similar outcomes.